Cancer Breast Comprehensive Panel Test
Comprehensive Breast Cancer Biomarker Analysis
The Cancer Breast Comprehensive Panel Test represents a cutting-edge diagnostic approach in breast cancer management, providing essential biomarker information that guides personalized treatment strategies. This comprehensive analysis evaluates multiple critical biomarkers simultaneously, offering healthcare providers a complete picture of tumor characteristics to optimize therapeutic decisions.
What This Test Measures and Detects
Our advanced panel utilizes sophisticated laboratory techniques to assess four crucial breast cancer biomarkers:
- IHC ERBB2 (HER-2) with reflex to FISH: Evaluates HER2 protein expression levels and gene amplification status, determining eligibility for targeted HER2 therapies
- Estrogen Receptor (ER): Measures estrogen receptor expression, indicating potential responsiveness to hormone therapy
- Progesterone Receptor (PR): Assesses progesterone receptor status, providing additional information about hormone sensitivity
- Ki67: Measures cellular proliferation rate, offering insights into tumor aggressiveness and growth potential
Who Should Consider This Test
This comprehensive panel is particularly valuable for individuals who:
- Have received a recent breast cancer diagnosis
- Require detailed biomarker profiling for treatment planning
- Need confirmation of hormone receptor status
- Require HER2 status determination for targeted therapy consideration
- Seek comprehensive tumor characterization beyond basic pathology
- Are undergoing treatment evaluation or monitoring
Clinical Benefits and Importance
The Cancer Breast Comprehensive Panel offers numerous advantages for patients and healthcare providers:
- Personalized Treatment Planning: Enables tailored therapy selection based on individual tumor characteristics
- Targeted Therapy Guidance: Identifies patients who may benefit from specific targeted treatments
- Prognostic Information: Provides insights into disease progression and potential outcomes
- Comprehensive Analysis: Multiple biomarkers assessed in a single test for efficiency
- Evidence-Based Decisions: Supports treatment choices with robust scientific data
Understanding Your Test Results
Your comprehensive panel results will include detailed information about each biomarker:
- HER2 Status: Positive results indicate potential benefit from HER2-targeted therapies, while negative results suggest alternative treatment approaches
- Hormone Receptor Status: Positive ER and/or PR results typically indicate responsiveness to hormone-blocking treatments
- Ki67 Proliferation Index: Higher percentages may indicate more aggressive tumor behavior
- Integrated Interpretation: Your oncologist will combine all biomarker results to develop a comprehensive treatment strategy
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Cancer Breast Comprehensive Panel Test | $250 USD | $376 USD |
Nationwide Accessibility
We maintain comprehensive diagnostic facilities across the United States, with branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our nationwide network ensures convenient access to advanced breast cancer testing services regardless of your location.
Schedule Your Test Today
Take the next step in your breast cancer journey with comprehensive biomarker analysis. Our experienced team is ready to assist you with scheduling and answer any questions about the testing process. Contact us today to book your Cancer Breast Comprehensive Panel Test and gain valuable insights for your treatment planning.
Call or WhatsApp: +1(267) 388-9828
Note: Sample collection requires submission of tumor tissue in 10% Formalin or Formalin fixed paraffin embedded tissue block. Please provide a copy of your Histopathology report, clinical history, and indicate the site of biopsy. Samples should be shipped at room temperature. Results are typically available within 10 working days when samples are received by Tuesday at 9 AM.
